CN106237348A - 一种医用超声耦合剂及其制备方法 - Google Patents
一种医用超声耦合剂及其制备方法 Download PDFInfo
- Publication number
- CN106237348A CN106237348A CN201610688468.3A CN201610688468A CN106237348A CN 106237348 A CN106237348 A CN 106237348A CN 201610688468 A CN201610688468 A CN 201610688468A CN 106237348 A CN106237348 A CN 106237348A
- Authority
- CN
- China
- Prior art keywords
- coupling agent
- ultrasonic coupling
- carbomer
- cellulose
- medical ultrasonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007822 coupling agent Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 31
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960001631 carbomer Drugs 0.000 claims abstract description 28
- 239000001913 cellulose Substances 0.000 claims abstract description 18
- 229920002678 cellulose Polymers 0.000 claims abstract description 18
- 125000002091 cationic group Chemical group 0.000 claims abstract description 15
- 230000002070 germicidal effect Effects 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000080 wetting agent Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 26
- 230000008961 swelling Effects 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 4
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 229940082484 carbomer-934 Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 229960002233 benzalkonium bromide Drugs 0.000 claims 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims 1
- 229940043234 carbomer-940 Drugs 0.000 claims 1
- 229940031098 ethanolamine Drugs 0.000 claims 1
- 238000013329 compounding Methods 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 239000002562 thickening agent Substances 0.000 abstract description 5
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 229960003500 triclosan Drugs 0.000 abstract description 4
- 230000036571 hydration Effects 0.000 abstract description 3
- 238000006703 hydration reaction Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000004062 sedimentation Methods 0.000 abstract description 2
- 150000001298 alcohols Chemical class 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开一种医用超声耦合剂及其制备方法,该超声耦合剂包括以下质量比的原料:醇类1%~10%;阳离子杀菌剂0.1%~3%;卡波姆0.05~2%;纤维素0.05~2%;保湿剂0.1%~5%;中和剂0.1%~2%;余量的纯水。本发明超声耦合剂以阳离子杀菌剂为主要杀菌成分,避免了使用三氯生带来的毒副作用;以醇类物质对阳离子杀菌剂进行保护后,添加卡波姆与纤维素复配的增稠剂,使阳离子杀菌剂与卡波姆复配良好,解决了二者复配产生的沉淀问题。同时由于单独使用卡保姆极易发生水化作用,本发明以卡波姆复配纤维素,作为体系的增稠剂,既避免了单独使用纤维素带来的黏腻,也避免了单独使用卡波姆引起的水化。
Description
技术领域
本发明涉及一种医用超声耦合剂,尤其涉及一种具有杀菌功能且同时具有保湿润肤作用的医用超声耦合剂及其制备方法。
背景技术
在超声诊断与治疗的过程中,超声探头与皮肤之间由于空气的存在会导致声波的衰减,清晰的超声成像需要以超声耦合剂作为超声探头与皮肤之间的介质,隔绝空气声阻对超声波的反射,透射声波,消除由于空气反射造成的能量损失与成像不清晰。
医院超声探头使用频率高,且用后没有完善的消毒处理措施,简单擦拭后进入下一个病人的检查。因此带有杀菌功能的超声耦合剂可减少由于超声探头引起的细菌交叉感染;以三氯生作为主要杀菌成分的超声耦合剂,由于三氯生的致畸致癌作用,进而带来一定的危害;葡萄糖酸洗必泰为一种使用安全,毒副作用小的杀菌剂,但由于和卡波姆增稠剂复配的过程中造成阴阳离子反应生成沉淀,限制了其应用;同时目前市面上常用的消毒超声耦合剂肤感黏腻,易给患者造成精神与心理上的干扰;而以卡波姆为主要增稠成分的耦合剂,由于卡波姆的遇到皮肤的水化作用,造成耦合剂的媒介作用很快消失,且水化后沿皮肤流动。
发明内容
针对上述现有技术中的不足,本发明提供了一种具有杀菌功能且肤感较好保湿润肤的医用超声耦合剂及其制备方法。该超声耦合剂具有快速杀菌的作用,减少不同患者之间由于超声探头造成的交叉感染,同时具有保湿润肤作用,减少用后的干燥,瘙痒,过敏等症状。
为实现上述目的之一提供一种医用超声耦合剂,本发明采用了以下技术方案:
一种医用超声耦合剂,该超声耦合剂包括以下质量比的原料:
烷基醇 1%~10%;
阳离子杀菌剂 0.1%~3%;
卡波姆 0.05~2%;
纤维素 0.05~2%;
保湿剂 0.1%~5%;
中和剂 0.1%~2%;
余量的纯水。
优选的,该超声耦合剂包括以下质量比的原料:
烷基醇 2%~6%;
阳离子杀菌剂 0.5%~1.5%;
卡波姆 0.1~1%;
纤维素 0.1~1%;
保湿剂 0.2%~5%;
中和剂 0.2%~0.8%;
余量的纯水。
进一步的,所述烷基醇为乙醇,正丙醇,丙三醇中的任一种或多种。
进一步的,所述阳离子杀菌剂为葡萄糖酸氯已定,醋酸氯已定,苄索氯胺,苯扎溴铵中的任一种或多种。
进一步的,所述卡波姆为卡波姆940,卡波姆980,卡波姆1342,卡波姆ETD 2020,卡波姆U20,卡波姆U21中的任一种或多种。
进一步的,所述纤维素为羧甲基纤维素,羟丙基甲基纤维素,甲基纤维素,羟乙基纤维素中的任一种或多种。
进一步的,所述保湿剂为丙氨酸,甘氨酸,脯氨酸,天冬氨酸,赖氨酸,缬氨酸,亮氨酸中的任一种或多种。
进一步的,所述中和剂为三乙醇胺。
进一步的,所述超声耦合剂的pH为6.8~7.4。
本发明还提供了一种医用超声耦合剂的制备方法,包括如下步骤:以质量分数计;
S1、称取0.1%~3%的阳离子杀菌剂,加入1%~10%的烷基醇中溶解,得溶液A;
S2、称取0.05~2%的卡波姆和0.05~2%的纤维素,加入80%的纯水,搅拌溶胀;
S3、在卡波姆和纤维素溶胀液中加入0.1%~2%的中和剂,搅拌均匀,得溶液B;
S4、将溶液A加入溶液B中,搅拌均匀;
S5、向步骤S4所得溶液中加入0.1%~5%的保湿剂;
S6、调节溶液pH为6.8~7.4,将余下的纯水补加完全;
S7、搅拌均匀,灌装;即得医用超声耦合剂。
本发明的有益效果在于:
1)、本发明超声耦合剂以阳离子杀菌剂为主要杀菌成分,避免了使用三氯生带来的毒副作用;以烷基醇对阳离子杀菌剂进行保护后,添加卡波姆与纤维素复配的增稠剂,使阳离子杀菌剂与卡波姆复配良好,解决了二者复配产生的沉淀问题。同时由于单独使用卡保姆极易发生水化作用,本发明以卡波姆复配纤维素,作为体系的增稠剂,既避免了单独使用纤维素带来的黏腻,也避免了单独使用卡波姆引起的水化;提高了本发明产品的可靠性。
2)、本发明超声耦合剂,具有杀菌功能,防止不同患者之间由于超声探头带来的交叉感染,同时添加多种氨基酸作为保湿剂,具有保湿润肤作用,减少用后的干燥,瘙痒,过敏等症状。
3)、本发明制备方法简单易行,便于推广应用。
具体实施方式
下面将结合本发明实施例,对本发明中的技术方案进行清楚、完整地描述。以下实施例仅用于更加清楚地说明本发明的技术方案,而不能以此来限制本发明的保护范围。
实施例1
超声耦合剂,包括以下质量的原料:
按如下步骤进行超声耦合剂的制备:
S1、精确称取葡萄糖酸氯已定1g,加入10g乙醇中,搅拌溶解,得溶液A;
S2、称取0.3g卡波姆940,0.2g羟丙基甲基纤维素,加入80g纯水中,搅拌溶胀2h;
S3、向S2中溶胀液中加入0.4g三乙醇胺,搅拌均匀,得溶液B;
S4、将溶液A加入到溶液B中,搅拌均匀;
S5、向S4所得溶液中分别加入甘氨酸0.2g,丙氨酸0.1g,赖氨酸0.1g,搅拌均匀;
S6、调节pH至6.8,加入7.7g纯水,搅拌均匀。
S7、灌装既得成品。
实施例2
超声耦合剂,由以下质量比的原料组成:
按如下步骤进行超声耦合剂的制备:
S1、精确称取醋酸氯已定0.6g,加入8g正丙醇中,搅拌溶解,得溶液A;
S2、称取0.1g卡波姆980,0.2g甲基纤维素,加入80g纯水中,搅拌溶胀2h;
S3、向S2中溶胀液中加入0.3g三乙醇胺,搅拌均匀,得溶液B;
S4、将溶液A加入到溶液B中,搅拌均匀;
S5、向S4所得溶液中分别加入缬氨酸0.2g,天冬氨酸0.3g,搅拌均匀;
S6、调节pH至7,加入10.3g纯水,搅拌均匀。
S7、灌装既得成品。
实施例3
超声耦合剂,由以下质量比的原料组成:
按如下步骤进行超声耦合剂的制备:
S1、精确称取苄索氯胺0.8g,加入6g乙醇中,搅拌溶解,得溶液A;
S2、称取0.15g卡波姆ETD 2020,0.2g羟乙基纤维素,加入80g纯水中,搅拌溶胀2h;
S3、向S2中溶胀液中加入0.2g三乙醇胺,搅拌均匀,得溶液B;
S4、将溶液A加入到溶液B中,搅拌均匀;
S5、向S4所得溶液中分别加入缬氨酸0.2g,亮氨酸0.3g,甘氨酸0.1g,搅拌均匀;
S6、调节pH至7.4,加入12.05g纯水,搅拌均匀。
S7、灌装既得成品。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和变形,这些改进和变形也应视为本发明的保护范围。
Claims (10)
1.一种医用超声耦合剂,其特征在于,该超声耦合剂包括以下质量比的原料:
烷基醇1%~10%;
阳离子杀菌剂0.1%~3%;
卡波姆0.05~2%;
纤维素0.05~2%;
保湿剂0.1%~5%;
中和剂0.1%~2%;
余量的纯水。
2.根据权利要求1所述的一种医用超声耦合剂,其特征在于,该超声耦合剂包括以下质量比的原料:
烷基醇2%~6%;
阳离子杀菌剂0.5%~1.5%;
卡波姆0.1~1%;
纤维素0.1~1%;
保湿剂0.2%~5%;
中和剂0.2%~0.8%;
余量的纯水。
3.根据权利要求1或2所述的一种医用超声耦合剂,其特征在于:所述烷基醇为乙醇,正丙醇,丙三醇中的任一种或多种。
4.根据权利要求1或2所述的一种医用超声耦合剂,其特征在于:所述阳离子杀菌剂为葡萄糖酸氯已定,醋酸氯已定,苄索氯胺,苯扎溴铵中的任一种或多种。
5.根据权利要求1或2所述的一种医用超声耦合剂,其特征在于:所述卡波姆为卡波姆940,卡波姆980,卡波姆1342,卡波姆ETD 2020,卡波姆U20,卡波姆U21中的任一种或多种。
6.根据权利要求1或2所述的一种医用超声耦合剂,其特征在于:所述纤维素为羧甲基纤维素,羟丙基甲基纤维素,甲基纤维素,羟乙基纤维素中的任一种或多种。
7.根据权利要求1或2所述的一种医用超声耦合剂,其特征在于:所述保湿剂为丙氨酸,甘氨酸,脯氨酸,天冬氨酸,赖氨酸,缬氨酸,亮氨酸中的任一种或多种。
8.根据权利要求1或2所述的一种医用超声耦合剂,其特征在于:所述中和剂为三乙醇胺。
9.根据权利要求1或2所述的一种医用超声耦合剂,其特征在于:所述超声耦合剂的pH为6.8~7.4。
10.一种医用超声耦合剂的制备方法,其特征在于包括如下步骤:以质量分数计;
S1、称取0.1%~3%的阳离子杀菌剂,加入1%~10%的醇类中溶解,得溶液A;
S2、称取0.05~2%的卡波姆和0.05~2%的纤维素,加入80%的纯水,搅拌溶胀;
S3、在卡波姆和纤维素溶胀液中加入0.1%~2%的中和剂,搅拌均匀,得溶液B;
S4、将溶液A加入溶液B中,搅拌均匀;
S5、向步骤S4所得溶液中加入0.1%~5%的保湿剂;
S6、调节溶液pH为6.8~7.4,将余下的纯水补加完全;
S7、搅拌均匀,灌装;即得医用超声耦合剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610688468.3A CN106237348A (zh) | 2016-08-18 | 2016-08-18 | 一种医用超声耦合剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610688468.3A CN106237348A (zh) | 2016-08-18 | 2016-08-18 | 一种医用超声耦合剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106237348A true CN106237348A (zh) | 2016-12-21 |
Family
ID=57591772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610688468.3A Pending CN106237348A (zh) | 2016-08-18 | 2016-08-18 | 一种医用超声耦合剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106237348A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109248320A (zh) * | 2017-07-12 | 2019-01-22 | 北京甲护生物科技有限公司 | 一种稳定的高氧化酸性电位水医用超声耦合剂 |
CN109289059A (zh) * | 2018-11-28 | 2019-02-01 | 广州润虹医药科技股份有限公司 | 一种杀菌型医用超声耦合剂及其制备方法 |
CN113069561A (zh) * | 2021-06-04 | 2021-07-06 | 广州市一杰医药科技有限公司 | 一种具有消毒功能的医用超声耦合剂及制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766552A (zh) * | 2010-01-20 | 2010-07-07 | 华南理工大学 | 一种免洗抗菌洗手液及其制备方法 |
CN102178963A (zh) * | 2011-04-13 | 2011-09-14 | 张英联 | 医用超声耦合剂及其制备方法 |
CN102188723A (zh) * | 2011-04-22 | 2011-09-21 | 北京道行中孚科技有限公司 | 一种免擦拭医用超声耦合剂及其制备方法 |
CN102430132A (zh) * | 2011-12-14 | 2012-05-02 | 威海西施康生物工程有限公司 | 一种消毒杀菌型医用超声耦合剂 |
CN105030661A (zh) * | 2015-08-14 | 2015-11-11 | 稳健医疗用品股份有限公司 | 一种消毒凝胶及其制备方法 |
CN105362212A (zh) * | 2015-12-18 | 2016-03-02 | 南京巨鲨显示科技有限公司 | 一种免洗手消毒凝胶及其制备方法 |
-
2016
- 2016-08-18 CN CN201610688468.3A patent/CN106237348A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766552A (zh) * | 2010-01-20 | 2010-07-07 | 华南理工大学 | 一种免洗抗菌洗手液及其制备方法 |
CN102178963A (zh) * | 2011-04-13 | 2011-09-14 | 张英联 | 医用超声耦合剂及其制备方法 |
CN102188723A (zh) * | 2011-04-22 | 2011-09-21 | 北京道行中孚科技有限公司 | 一种免擦拭医用超声耦合剂及其制备方法 |
CN102430132A (zh) * | 2011-12-14 | 2012-05-02 | 威海西施康生物工程有限公司 | 一种消毒杀菌型医用超声耦合剂 |
CN105030661A (zh) * | 2015-08-14 | 2015-11-11 | 稳健医疗用品股份有限公司 | 一种消毒凝胶及其制备方法 |
CN105362212A (zh) * | 2015-12-18 | 2016-03-02 | 南京巨鲨显示科技有限公司 | 一种免洗手消毒凝胶及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109248320A (zh) * | 2017-07-12 | 2019-01-22 | 北京甲护生物科技有限公司 | 一种稳定的高氧化酸性电位水医用超声耦合剂 |
CN109289059A (zh) * | 2018-11-28 | 2019-02-01 | 广州润虹医药科技股份有限公司 | 一种杀菌型医用超声耦合剂及其制备方法 |
CN109289059B (zh) * | 2018-11-28 | 2021-04-27 | 广州润虹医药科技股份有限公司 | 一种杀菌型医用超声耦合剂及其制备方法 |
CN113069561A (zh) * | 2021-06-04 | 2021-07-06 | 广州市一杰医药科技有限公司 | 一种具有消毒功能的医用超声耦合剂及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106237348A (zh) | 一种医用超声耦合剂及其制备方法 | |
CN101991868B (zh) | 消毒杀菌润肤型医用超声耦合剂及其制备方法 | |
WO2015016727A4 (en) | Oral dispersible films | |
DE3119017A1 (de) | Entzuendungshemmende und analgetische gel-zusammensetzungen | |
JP2001192326A (ja) | 染色毛髪用処理組成物 | |
BRPI0815203B1 (pt) | gel contendo pirfenidona | |
CN101920042A (zh) | 一种液体创口贴及制备方法 | |
CN101716354A (zh) | 一种超声耦合剂和应用 | |
CN101612408A (zh) | B超耦合剂及制备方法 | |
CN109381348B (zh) | 一种稳定的高含量胶原蛋白透明化妆水 | |
CN104258427A (zh) | 用于创面超声诊断的杀菌型医用超声耦合剂及其制备方法 | |
JPWO2016185811A1 (ja) | 超音波診断用の塗布型接触媒体 | |
CN107638304B (zh) | 一种高皮肤细胞渗透的α-熊果苷组合物及其制备方法和应用 | |
JPH02264723A (ja) | 抗真菌剤 | |
CN108714162A (zh) | 一种治疗灰指甲的外用药物 | |
JP5184726B2 (ja) | グルコサミン含有パップ剤 | |
CN102430132A (zh) | 一种消毒杀菌型医用超声耦合剂 | |
CN107753961B (zh) | 一种心脏彩超超声耦合剂 | |
Ahmed et al. | Acute kidney injury following usage of formaldehyde-free hair straightening products | |
JPH07126158A (ja) | クロタミトン配合外用剤 | |
JP5959271B2 (ja) | 粘膜適用組成物 | |
JP6125141B2 (ja) | 点眼剤 | |
JP6047295B2 (ja) | 粘膜適用組成物 | |
JP6026192B2 (ja) | カルボキシメチルキトサンアセテート化合物、その製造方法及び化粧料 | |
JP4209215B2 (ja) | 超音波診断用の塗布型接触媒体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161221 |
|
RJ01 | Rejection of invention patent application after publication |